Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | FFAR3 | O14843 | 3/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.39 |
| ▸ | FDPS | P14324 | 2/20 | 0.39 |
| ▸ | ENO1 | P06733 | 1/20 | 0.39 |
| ▸ | METAP1 | P53582 | 1/20 | 0.38 |
| ▸ | PGK1 | P00558 | 1/20 | 0.38 |
| ▸ | PGK2 | P07205 | 1/20 | 0.38 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3005295 | 0.85 | CA1 (0.46) | TSHRMEN1LMNAHPGDBLM | |
| SCHEMBL3002275 | 0.83 | KMT2A (0.50) | TSHRMEN1KMT2ATDP1CES2 | |
| SCHEMBL7741804 | 0.81 | KMT2A (0.54) | TSHRMEN1KMT2ATDP1CES2 | |
| SCHEMBL10709425 | 0.81 | KMT2A (0.54) | TSHRMEN1KMT2ATDP1CES2 | |
| SCHEMBL8414887 | 0.81 | KMT2A (0.54) | TSHRMEN1KMT2ATDP1CES2 | |
| SCHEMBL8584405 | 0.81 | KMT2A (0.54) | TSHRMEN1KMT2ATDP1CES2 | |
| SCHEMBL8583505 | 0.81 | KMT2A (0.54) | TSHRMEN1KMT2ATDP1CES2 | |
| SCHEMBL16655824 | 0.80 | HDAC3 (0.42) | TSHRCES2CES1FFAR3HDAC3 | |
| SCHEMBL15550971 | 0.78 | FDPS (0.35) | TSHRMEN1LMNAHPGDBLM | |
| SCHEMBL3074006 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220194920-A1 | HETEROARYL(HETEROCYCLYL)METHANOL COMPOUNDS USEFUL IN THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2022-06-23 | — | — | US | disclosed |
| EP-3941913-A1 | HETEROARYL(HETEROCYCLYL)METHANOL COMPOUNDS USEFUL IN THE TREATMENT OF HYPERGLYCAEMIA | Atrogi AB (SE) | 2022-01-26 | — | — | EP | disclosed |
| WO-2020188299-A1 | HETEROARYL(HETEROCYCLYL)METHANOL COMPOUNDS USEFUL IN THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2020-09-24 | — | — | WO | disclosed |
| US-20100191019-A1 | Organic Compounds | GIVAUDAN SA (CH) | 2010-07-29 | — | — | US | disclosed |
| EP-2178399-A1 | ORGANIC COMPOUNDS | Givaudan SA (CH) | 2010-04-28 | — | — | EP | disclosed |
| WO-2009009916-A1 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2009-01-22 | — | — | WO | disclosed |
| US-4959360-A | α-adrenergic receptor antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1990-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100191019-A1 | Organic Compounds | OR10J3, ALOX5, OR51E2 | TSHR 4300/4885MEN1 4723/4885LMNA 2248/4885 |
| US-20220194920-A1 | HETEROARYL(HETEROCYCLYL)METHANOL COMPOUNDS USEFUL IN THE TREATMENT OF HYPERGLYCAEMIA | SLC5A1, GPR119, SLC5A2 | TSHR 1551/4885MEN1 33/4885LMNA 1919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.